AbbVie (ABBV) Income from Continuing Operations (2012 - 2026)

AbbVie has disclosed Income from Continuing Operations across 15 years of filings, most recently posting 697000000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations fell 45.93% year-over-year to 697000000.0; the TTM figure through Mar 2026 stood at 3641000000.0 (down 13.37% YoY), while the FY2025 annual figure was 4233000000.0, down 1.24% from the prior year.
• Income from Continuing Operations declined to 697000000.0 in Q1 2026, from 1815000000.0 in the prior quarter.
• Over the last five years, Income from Continuing Operations for ABBV reached as high as 4493000000.0 in Q1 2022 and fell as low as 97000000.0 in Q1 2023.
• The 5-year median for Income from Continuing Operations is 1372000000.0 (2024), against an average of 1505647058.82.
• Annual changes were most pronounced in 2024 — Income from Continuing Operations sank 102.79% — and 2025, when it surged 7991.3%.
• A 5-year view of Income from Continuing Operations shows it stood at 2472000000.0 in 2022, then tumbled by 66.67% to 824000000.0 in 2023, then slumped by 102.79% to 23000000.0 in 2024, then surged by 7991.3% to 1815000000.0 in 2025, then sank by 61.6% to 697000000.0 in 2026.
• According to Business Quant data, Income from Continuing Operations over the past three periods registered 697000000.0, 1815000000.0, and 188000000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.